Indivior
INDV
$35.05
+1.42%
Indivior Pharmaceuticals is a specialty pharmaceutical company singularly focused on developing and commercializing treatments for opioid use disorder (OUD), with key products including Sublocade, a monthly extended-release buprenorphine injection, and Suboxone sublingual film. As a market leader in the OUD treatment space, Indivior holds a distinct competitive position due to its specialized focus and established brand portfolio. The current investor narrative centers on the company's growth trajectory, driven by Sublocade adoption and a recent merger agreement with Supernus Pharmaceuticals, which promises $125 million in annual synergies but also introduces execution risks. Additionally, the stock has experienced significant volatility, with a 46% gain over the past year but a recent pullback, reflecting market debates over merger integration, competitive pressures, and the sustainability of its growth.…
INDV
Indivior
$35.05
Related headlines
Investment Opinion: Should I buy INDV Today?
Based on the analysis, I rate INDV as a Buy, driven by its strong revenue growth, high gross margins, and significant upside to analyst targets. The average analyst target of $49.00 implies a 40.5% upside, and the forward P/E of 7.14x suggests the market is pricing in substantial earnings growth, which is supported by the merger synergies and Sublocade adoption. However, the negative free cash flow and high debt levels are concerning, and the rating would be downgraded to Hold if the merger fails to deliver synergies or if revenue growth decelerates below 10%.
Sign up to view all
INDV 12-Month Price Forecast
The AI assessment leans bullish due to the strong growth trajectory and attractive valuation, but confidence is medium given the financial red flags. The key to the thesis is whether the company can achieve the projected earnings growth, which hinges on merger success and cash flow improvement. If the company reports another quarter of strong revenue growth and positive free cash flow, the stance would be upgraded to high confidence. Conversely, any signs of merger integration issues or deteriorating liquidity would prompt a downgrade to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Indivior's 12-month outlook, with a consensus price target around $49.00 and implied upside of +39.8% versus the current price.
Average Target
$49.00
0 analysts
Implied Upside
+39.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$43 - $53
Analyst target range
Indivior has coverage from 4 analysts, with a consensus recommendation of 'none' (no clear buy/hold/sell consensus), but the average target price is $49.00, implying an upside of approximately 40.5% from the current price of $34.87. The target range spans from a low of $43.00 to a high of $53.00, with the high target suggesting a 52% upside, reflecting optimism about merger synergies and growth potential, while the low target still implies a 23% upside, indicating that analysts see limited downside risk. The narrow spread between the low and high targets (23% to 52% upside) suggests a relatively high conviction in the stock's appreciation potential, though the lack of a formal consensus recommendation and the recent merger-related volatility warrant caution.
Bulls vs Bears: INDV Investment Factors
Indivior presents a compelling growth story with strong revenue acceleration, high gross margins, and significant analyst upside, but it is tempered by concerning financial metrics such as negative free cash flow and a high debt-to-equity ratio. The bull case is currently stronger, driven by the potential for merger synergies and the low forward P/E, but the bear case highlights execution and liquidity risks that could derail the thesis. The most critical tension is whether the company can convert its revenue growth into sustainable free cash flow and successfully integrate the Supernus merger, as this will determine if the optimistic forward earnings estimates are achievable.
Bullish
- Strong Revenue Growth: Q1 2026 revenue grew 19.17% YoY to $317M, with sequential growth from $266M in Q1 2025 to $358M in Q4 2025, indicating accelerating momentum driven by Sublocade adoption.
- High Gross Margin: Gross margin is 80.1% (TTM), reflecting a strong pricing power and cost structure typical of specialty pharmaceuticals, providing a solid foundation for profitability.
- Significant Analyst Upside: Analysts' average target price is $49.00, implying a 40.5% upside from the current price of $34.87, with the low target of $43.00 still offering a 23% upside, indicating limited downside risk.
- Merger Synergies: The merger with Supernus is expected to unlock $125 million in annual synergies, which could significantly boost earnings and justify the low forward P/E of 7.14x.
Bearish
- Negative Free Cash Flow: TTM free cash flow is -$184.6M, indicating that the company is burning cash despite reported profits, which could constrain financial flexibility and increase reliance on debt or equity.
- High Debt-to-Equity: Debt-to-equity is -3.58x, reflecting negative equity (likely due to accumulated losses or buybacks), which raises solvency concerns and financial risk.
- Recent Price Decline: The stock has fallen 13.04% in the past month and 3.19% in the past three months, underperforming the S&P 500, which gained 5.47% and 1.7% respectively, indicating negative momentum.
- Merger Execution Risks: The Supernus merger, while promising synergies, carries integration risks that could disrupt operations or fail to deliver expected cost savings, as highlighted in recent news.
INDV Technical Analysis
Indivior's stock has demonstrated a strong long-term uptrend, with a 1-year price change of +46.02%, significantly outperforming the S&P 500's +18.56% over the same period. The current price of $34.87 sits at approximately 63% of its 52-week range (low of $22.22, high of $42.81), indicating that while the stock has retreated from its highs, it remains well above its lows, suggesting a consolidation phase after a substantial rally. This positioning implies that the market is digesting recent gains, and the stock is neither overextended at highs nor at distressed lows, offering a balanced risk-reward profile.
Beta
1.14
1.14x market volatility
Max Drawdown
-21.4%
Largest decline past year
52-Week Range
$22-$43
Price range past year
Annual Return
+42.5%
Cumulative gain past year
| Period | INDV Return | S&P 500 |
|---|---|---|
| 1m | -6.2% | +1.0% |
| 3m | -6.4% | +1.1% |
| 6m | +8.6% | +13.8% |
| 1y | +42.5% | +19.5% |
| ytd | -1.9% | +12.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
INDV Fundamental Analysis
Indivior's revenue trajectory has been robust, with the most recent quarter (Q1 2026) reporting revenue of $317 million, a 19.17% year-over-year growth rate, and a sequential increase from $266 million in Q1 2025. Over the past four quarters, revenue has grown from $302 million in Q2 2025 to $358 million in Q4 2025, indicating accelerating growth, driven primarily by strong Sublocade sales. The company's top-line expansion is a key positive, reflecting increasing adoption of its long-acting injectable treatment and a growing OUD patient population.
Quarterly Revenue
$316999999.0B
2026-03
Revenue YoY Growth
+19.2%
YoY Comparison
Gross Margin
87.4%
Latest Quarter
Free Cash Flow
$-184619260.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is INDV Overvalued?
Given that Indivior is profitable with a trailing net income of $89 million, the primary valuation metric selected is the P/E ratio. The trailing P/E stands at 21.36x, while the forward P/E is significantly lower at 7.14x, implying that the market expects substantial earnings growth in the coming year. This wide gap between trailing and forward multiples suggests that analysts anticipate a major earnings acceleration, likely driven by merger synergies and continued Sublocade growth, but it also raises questions about the achievability of such optimistic forecasts.
PE
21.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 6x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant, with a negative free cash flow of -$184.6M TTM indicating that the company is not generating enough cash to cover its capital expenditures and working capital needs. The debt-to-equity ratio of -3.58x reflects negative shareholder equity, which could be a red flag for solvency, and the current ratio of 0.71 suggests potential liquidity constraints. These factors could limit the company's ability to invest in growth or weather downturns, and any further deterioration could lead to credit downgrades or equity dilution.
FAQ
The key risks include: 1) Financial risk from negative free cash flow of -$184.6M and high debt-to-equity of -3.58x, which could lead to liquidity issues. 2) Execution risk from the Supernus merger, which may not deliver the $125M in synergies. 3) Competitive risk from generic alternatives or new treatments for OUD. 4) Market risk, as the stock has a beta of 1.136, making it more volatile than the market. The most severe risk is a merger failure, which could send the stock down to the 52-week low of $22.22, a 36% loss.
The 12-month forecast is bullish, with a base case target of $49 (40.5% upside) and a bull case target of $53 (52% upside), while the bear case could see the stock fall to $22 (36% downside). The base case has a 50% probability and assumes moderate growth and successful merger integration. The most likely scenario is the base case, driven by continued Sublocade adoption and synergies, but investors should monitor cash flow and merger progress.
Based on the forward P/E of 7.14x, INDV appears undervalued relative to its expected earnings growth, especially when considering the PEG ratio of 0.0019, which is extremely low. However, the trailing P/E of 21.36x suggests the market is pricing in a significant earnings jump, which may be optimistic. Compared to peers, the stock trades at a discount on forward earnings, but the negative free cash flow and high debt warrant a discount. Overall, the valuation implies the market expects substantial growth, and if that fails to materialize, the stock could be overvalued.
INDV offers a compelling risk/reward with a 40.5% upside to the average analyst target of $49.00, but it carries significant risks due to negative free cash flow and high debt. The stock is a good buy for investors who believe in the merger synergies and can tolerate volatility, but it may not be suitable for conservative investors. If the merger succeeds and cash flow improves, the stock could re-rate higher, but if integration fails, downside to the 52-week low of $22.22 is possible.
INDV is more suitable for long-term investment, given its growth potential and the expected merger synergies, but it is also volatile with a beta of 1.136. The stock has shown strong 1-year performance (+46%) but recent pullbacks suggest short-term trading risks. A minimum holding period of 12-18 months is recommended to allow the merger to close and synergies to materialize, which could drive the stock to analyst targets. Short-term traders may find opportunities, but the high volatility and liquidity risks make it less ideal for short-term strategies.